Drug Database · Clinicians

Tretinoin

Brands (18) Dermese-A, Trunex, Acnecare…Show all

US brand (reference label): Tretinoin Cream; not a Philippine-registered brand.

Retinoid US FDA class
Anti-acne preparation for topical use; Anti-acne (retinoid); and others PH FDA category

Rx · Prescription drugOTC · Over-the-counterHR · Household remedy31 PH productsVAT-exempt
Dispensing: Household remedy (HR) · Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 745cc3ce-60b4-4479-a055-316817567949, version date February 11, 2025 (Tretinoin Cream · Obagi Cosmeceuticals LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Tretinoin is indicated for topical application in the treatment of acne vulgaris.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

Contraindications

CONTRAINDICATIONS Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Tretinoin Cream should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Application may cause a transitory feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or to reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment.

Alterations of vehicle, drug concentration, or dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. During the early weeks of therapy, an apparent exacerbation of inflammatory lesions may occur. This is due to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy.

Therapeutic results should be noticed after 2 to 3 weeks but more than 6 weeks of therapy may be required before definite beneficial effects are seen. Once the acne lesions have responded satisfactorily, it may be possible to maintain the improvement with less frequent applications, or other dosage forms. Patients treated with tretinoin acne treatment may use cosmetics, but the area to be treated should be cleansed thoroughly before the medication is applied (see PRECAUTIONS).

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Topical cream: 1 mg/g, 250 mcg/g, 500 mcg per g, 500 mcg/g
  • Cream: 0.06 mcg (0.006 % w/w) per 100 g, 6 mg (0.006 % w/w) per 100 g, 250 mcg/g, 500 mcg/g
  • Topical solution: 100 mcg per mL, 250 mcg/mL, 500 mcg/mL
  • Capsule: 10 mg
  • Per gram topical cream: 250 mcg

Registered products in the Philippines

31 products registered with the Food and Drug Administration (FDA) Philippines list Tretinoin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products31
Philippine FDA-registered products for Tretinoin
Package insert
AcnecareTretinoin
250 mcg/g (0.025% w/w) CreamAluminum Collapsible Tube x 10 g with cap (Box of 1's)
HRVAT-exempt
Yash Medicare Private LimitedIndia
Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRHR-1936
Jul 31, 2029
Acnoin-TTretinoin
500 mcg/g (0.05%) CreamPlastic Tube (70% LDPE, 25% LLDPE and 5% HDPE) x 30g (Box of 1's)
RxVAT-exempt
Zee LaboratoriesIndia
EON Pharmatek, Inc
DRP-15019
Jun 8, 2031
Age Defying CreamTretinoin
500 mcg/g (0.05% w/w) CreamPlastic Tube x 30 g (Box of 1's)
RxVAT-exempt
Zee LaboratoriesIndia
Intelligent Beauty Skin Solutions, Inc.Importer: Eon Pharmatek Inc.
DR-XY47305
Jun 18, 2031
Beautamin-A 0.025%Tretinoin
250 mcg/g (0.025% w/w) Topical CreamLDPE Aluminum Squeezable Tube with nozzle & cap x 10g and 30g (Box of I's)
HRVAT-exempt
Carmel Laboratories, Inc.Philippines
Trader: A.R.M. Skin Essentials, Corp
HRP-543
Sep 14, 2027
Beautederm Night Cream 1Tretinoin
6 mg (0.006% w/w) per 100 g CreamPET Jar with Cap x 20
HRVAT-exempt
DJM Grandeur CorporationPhilippines
Trader: Perfectskin Beauty Products Inc.
HRP-485
Nov 24, 2026
Beutamin-A 0.05%Tretinoin
500mcg per g (0.05% w/w) Topical CreamLDPE Aluminum Squeezable Tube x 10g and 30g with Nozzle and Cover (Box of 1s')
HRVAT-exempt
Carmel Laboratories, Inc.Philippines
Trader: A.R.M. Skin Essentials Corp.
HRP-547
Sep 23, 2027
Blanc By Beautederm Acne BanishingTretinoin
0.06 mcg (0.006% w/w) per 100 g CreamPP JAR WITH COVER, 5 AND 10 G
OTCVAT-exempt
DJM Grandeur CorporationPhilippines
Trader: Beautederm Corporation
DRP-12019
May 31, 2027
Dermese-ATretinoin
0.05% Gel10g Aluminum Collapsible Tube Not applicable
RxVAT-exempt
MCB Dermatological ProductsPhilippines
—
DR-XY26634
Oct 16, 2030
Dermese-ATretinoin
500 mcg/g (0.05%) Cream10 g Aluminum Tube with HDPE Screw Cap (Box of 1's)
HRVAT-exempt
MCB DERMATOLOGICAL PRODUCTSPhilippines
—
DRHR-1721
Aug 21, 2028
NoneTretinoin
0.025% Topical Cream500g HDPE Jar with PP Cap
RxVAT-exempt
STALDER LABORATORIES, INC.Philippines
Trader: BCP DERMATOLOGICAL CORP.
DR-XY38759
Nov 18, 2027
NoneTretinoin
0.05% w/w CreamAluminum Collapsible Tube x 10 g (Box of 1's); Aluminum Collapsible Tube x 3.5 g (Physician's Sample)
RxVAT-exempt
Stalder Laboratories, Inc.Philippines
BCP Dermatological Corporation
DRP-5856
May 19, 2031
NoneTretinoin
100 mcg per mL (0.01% w/v) Topical SolutionPET Bottle x 60 mL
HRVAT-exempt
Altum International Cosmeceutical Manufacturing Inc.Philippines
—
DRHR-2356
May 10, 2029
NoneTretinoin
100 mcg per mL (0.01% w/v) Topical SolutionPET Bottle x 60mL
HRVAT-exempt
Altum International Cosmeceutical Manufacturing Inc.Philippines
—
HRP-658
May 10, 2029
NoneTretinoin
250 mcg / g (0.025% w/w) Topical CreamPET Jar x 10 g
HRVAT-exempt
Altum International Cosmeceutical Manufacturing Inc.Philippines
—
HRP-657
May 10, 2029
NoneTretinoin
250 mcg/g (0.025% w/w) Topical CreamPET Jar x 10 g
HRVAT-exempt
Altum International Cosmeceutical Manufacturing Inc.Philippines
—
DRHR-2359
May 10, 2029
NoneTretinoin
500 mcg/g (0.05% w/w) CreamPolypropylene (PP) Micro-Oval Bottle x 25 g (Box of 1's)
RxVAT-exempt
Gruppo Medica, Inc.Philippines
Trader: Time Machine Cosmetiques, Inc.
DR-XY33436
Jun 6, 2029
NoneTretinoin
500 mcg/g (0.05% w/w) Topical CreamHDPE Jar with PP Cap x 500 g
RxVAT-exempt
Stalder Laboratories, Inc.Philippines
Trader: BCP Dermatological Corp.
DR-XY38758
Nov 18, 2027
NoneTretinoin
500 mcg/mL (0.05%) Topical SolutionHDPE Bottle with screw cap x 50 mL and 100 mL Not Applicable
RxVAT-exempt
MCB Dermatological ProductsPhilippines
—
DR-XY46841
Mar 12, 2031
NuDerm DermageTretinoin
1 mg/g (0.1% w/w) Topical CreamAluminum Tube with Plastic Screw Cap x 20 g Box of 1's
OTCVAT-exempt
Derm Pharma, Inc.Philippines
—
DR-XY29256
Sep 13, 2027
Oroderm Facial SolutionTretinoin
250 mcg/mL (0.025% w/v) Topical SolutionAmber Glass Bottle x 60 mL (Box of 1s)
OTCVAT-exempt
Oroderm CorporationPhilippines
—
DRHR-2074
Nov 3, 2031
Oroderm Night CreamTretinoin
500 mcg/g (0.05% w/w) CreamPP Jar x 15 g
OTCVAT-exempt
Oroderm CorporationLaguna
—
DRHR-2075
Nov 3, 2031
RetacnylTretinoin
500 mcg/g (0.05%) CreamAluminum Tube x 30 g (Box of 1's)
OTCVAT-exempt
Laboratoires GaldermaFrance
Galderma Philippines, Inc.
DR-XY20156
Mar 12, 2031
SaphtinoinTretinoin
250 mcg/g (0.025% w/w) Topical CreamCollapsible Aluminum Tube x 5 g, 10 g and 15 g (Box of l's)
OTCVAT-exempt
Azine Healthcare Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-10842
Dec 6, 2026
TreanTretinoin
250 mcg/g (0.025% w/w) CreamLaminated Tube x 15g With White Plastic Cap (Box of 1's)
RxVAT-exempt
Zhejiang Jingwei Pharmaceutical Co., Ltd.China
Aglobal Care, Inc.
HRP-433
Jun 25, 2031
TretinonTretinoin
500 mcg/g (0.05% w/w) Topical CreamAluminum Tube x 20 g (Box of 1's)
RxVAT-exempt
Y.S.P. Industries (M) Sdn. Bhd.Malaysia
Yung Shin (Philippines), Inc.
DR-XY47594
Dec 9, 2031
TrexonylTretinoin
500 mcg/g (0.05% w/w) Topical CreamLami tube x 30 g (Box of 1’s)
HRVAT-exempt
Nanz Med Science Pharma Pvt. Ltd.India
Pharma-Surrey International Inc.
HRP-753
Aug 5, 2031
TrunexTretinoin
250 mcg/g (0.025% w/w) Topical CreamLaminated Tube x 15g (Box of 1's)
HRVAT-exempt
KLM Laboratories Pvt. Ltd.India
AMB HK Enterprises Inc.
HRP-708
Sep 24, 2030
TrunexTretinoin
500 mcg/g (0.05% w/w) Topical CreamLaminated Tube x 15g (Box of 1's)
HRVAT-exempt
KLM Laboratories Pvt. Ltd.India
AMB HK Enterprises Inc.
HRP-709
Sep 24, 2030
UnbrandedTretinoin
0.025% w/w CreamAluminum Collapsible Tube x 10 g (Box of 1's); Aluminum Collapsible Tube x 3.5 g (Physician's Sample)
RxVAT-exempt
Stalder Laboratories, Inc.Laguna
Trader: BCP Dermatological Corporation
DRP-5855
May 19, 2031
VesanoidTretinoin
10 mg CapsuleAmber Glass Bottle x 100's (In a box)
RxVAT-exempt
Cheplapharm Arzneimittel GmBHGermany
Zuellig Pharma Corporation
DR-XY18526
Aug 10, 2027
(no brand name)Tretinoin
250 mcg (0.025% w/w) per gram Topical CreamHDPE Aluminum Collapsible Tube with Cap x 10 g & 20 g (Box of l's)
HRVAT-exempt
MCB Dermatological ProductsPhilippines
—
DRHR-2099
Nov 19, 2026

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

PRECAUTIONS General If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. Exposure to sunlight, including sunlamps, should be minimized during the use of tretinoin, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin.

Patients who may be required to have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with tretinoin.

Tretinoin acne treatment should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes. Topical use may induce severe local erythema and peeling at the site of application. If the degree of local irritation warrants, patients should be directed to use the medication less frequently, discontinue use temporarily, or discontinue use altogether.

Tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition. Drug Interactions Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin.

Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin. It also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of tretinoin is begun. Carcinogenesis, Mutagenesis, Impairment to Fertility In a 91-week dermal study in which CD-1 mice were administered 0.017% and 0.035% formulations of tretinoin, cutaneous squamous cell carcinomas and papillomas in the treatment area were observed in some female mice.

A dose-related incidence of liver tumors in male mice was observed at those same doses. The maximum systemic doses associated with the administered 0.017% and 0.035% formulations are 0.5 and 1.0 mg/kg/day, respectively. These doses are two and four times the maximum human systemic dose, when adjusted for total body surface area.

The biological significance of these findings is not clear because they occurred at doses that exceeded the dermal maximally tolerated dose (MTD) of tretinoin and because they were within the background natural occurrence rate for these tumors in this strain of mice. There was no evidence of carcinogenic potential when 0.025 mg/kg/day of tretinoin was administered topically to mice (0.1 times the maximum human systemic dose, adjusted for total body surface area).

For purposes of comparisons of the animal exposure to systemic human exposure, the maximum human systemic dose is defined as 1 gram of 0.1% RETIN-A applied daily to a 50 kg person (0.02 mg tretinoin/kg body weight). Studies in hairless albino mice suggest that concurrent exposure to tretinoin may enhance the tumorigenic potential of carcinogenic doses of UVB and UVA light from a solar simulator.

This effect has been confirmed in a later study in pigmented mice, and dark pigmentation did not overcome the enhancement of photocarcinogenesis by 0.05% tretinoin. Although the significance of these studies to humans is not clear, patients should minimize exposure to sunlight or artificial ultraviolet irradiation sources.

The mutagenic potential of tretinoin was evaluated in the Ames assay and in the in vivo mouse micronucleus assay, both of which were negative. In dermal Segment I fertility studies of another tretinoin formulation in rats, slight (not statistically significant) decreases in sperm count and motility were seen at 0.5 mg/kg/day (4 times the maximum human systemic dose adjusted for total body surface area) and slight (not statistically significant) increases in the number and percent of nonviable embryos in females treated with 0.25 mg/kg/day (2 times the maximum human systemic dose adjusted for total body surface area) and above were observed.

A dermal Segment III study with RETIN-A has not been performed in any species. In oral Segment I and Segment III studies in rats with tretinoin, decreased survival of neonates and growth retardation were observed at doses in excess of 2 mg/kg/day (16 times the human topical dose adjusted for total body surface area). Pregnancy Teratogenic Effects Oral tretinoin has been shown to be teratogenic in rats, mice, hamsters, and subhuman primates.

It was teratogenic and fetotoxic in Wistar rats when given orally or topically in doses greater than 1 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). However, variations in teratogenic doses among various strains of rats have been reported. In the cynomolgus monkey, which metabolically is closer to humans for tretinoin than the other species examined, fetal malformations were reported at doses of 10 mg/kg/day or greater, but none were observed at 5 mg/kg/day (83 times the maximum human systemic dose adjusted for total body surface area), although increased skeletal variations were observed at all doses.

A dose-related increase in embryolethality and abortion was reported. Similar results have also been reported in pigtail macaques. Topical tretinoin in animal teratogenicity tests has generated equivocal results. There is evidence for teratogenicity (shortened or kinked tail) of topical tretinoin in Wistar rats at doses greater than 1 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area).

Anomalies (humerus: short 13%, bent 6%, os parietale incompletely ossified 14%) have also been reported when 10 mg/kg/day was topically applied. There are other reports in New Zealand White rabbits administered doses of greater than 0.2 mg/kg/day (3.3 times the maximum human systemic dose adjusted for total body surface area) of an increased incidence of domed head and hydrocephaly, typical of retinoid-induced fetal malformations in this species.

In contrast, several well-controlled animal studies have shown that dermally applied tretinoin may be fetotoxic, but not overly teratogenic in rats and rabbits at doses of 1.0 and 0.5 mg/kg/day, respectively (8 times the maximum human systemic dose adjusted for total body surface area in both species). With widespread use of any drug, a small number of birth defect reports associated temporally with the administration of the drug would be expected by chance alone.

Thirty human cases of temporally associated congenital malformations have been reported during two decades of clinical use of RETIN-A. Although no definite pattern of teratogenicity and no causal association have been established from these cases, five of the reports describe the rare birth defect category holoprosencephaly (defects associated with incomplete midline development of the forebrain).

The significance of these spontaneous reports in terms of risk to the fetus is not known. Nonteratogenic Effects Topical tretinoin has been shown to be fetotoxic in rabbits when administered 0.5 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). Oral tretinoin has been shown to be fetotoxic, resulting in skeletal variations and increased intrauterine death in rats when administered 2.5 mg/kg/day (20 times the maximum human systemic dose adjusted for total body surface area).

There are, however, no adequate and well-controlled studies in pregnant women. Tretinoin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tretinoin is administered to a nursing woman.

Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 have not been established. Geriatric Use Safety and effectiveness in a geriatric population have not been established. Clinical studies of RETIN-A did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin. It also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of tretinoin is begun.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered.

Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin. To date, all adverse effects of tretinoin have been reversible upon discontinuance of therapy (see DOSAGE AND ADMINISTRATION).

To report SUSPECTED ADVERSE REACTIONS, contact Obagi Cosmeceuticals LLC at 1-800-636-7546 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects Oral tretinoin has been shown to be teratogenic in rats, mice, hamsters, and subhuman primates. It was teratogenic and fetotoxic in Wistar rats when given orally or topically in doses greater than 1 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). However, variations in teratogenic doses among various strains of rats have been reported.

In the cynomolgus monkey, which metabolically is closer to humans for tretinoin than the other species examined, fetal malformations were reported at doses of 10 mg/kg/day or greater, but none were observed at 5 mg/kg/day (83 times the maximum human systemic dose adjusted for total body surface area), although increased skeletal variations were observed at all doses. A dose-related increase in embryolethality and abortion was reported.

Similar results have also been reported in pigtail macaques. Topical tretinoin in animal teratogenicity tests has generated equivocal results. There is evidence for teratogenicity (shortened or kinked tail) of topical tretinoin in Wistar rats at doses greater than 1 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area).

Anomalies (humerus: short 13%, bent 6%, os parietale incompletely ossified 14%) have also been reported when 10 mg/kg/day was topically applied. There are other reports in New Zealand White rabbits administered doses of greater than 0.2 mg/kg/day (3.3 times the maximum human systemic dose adjusted for total body surface area) of an increased incidence of domed head and hydrocephaly, typical of retinoid-induced fetal malformations in this species.

In contrast, several well-controlled animal studies have shown that dermally applied tretinoin may be fetotoxic, but not overly teratogenic in rats and rabbits at doses of 1.0 and 0.5 mg/kg/day, respectively (8 times the maximum human systemic dose adjusted for total body surface area in both species). With widespread use of any drug, a small number of birth defect reports associated temporally with the administration of the drug would be expected by chance alone.

Thirty human cases of temporally associated congenital malformations have been reported during two decades of clinical use of RETIN-A. Although no definite pattern of teratogenicity and no causal association have been established from these cases, five of the reports describe the rare birth defect category holoprosencephaly (defects associated with incomplete midline development of the forebrain).

The significance of these spontaneous reports in terms of risk to the fetus is not known. Nonteratogenic Effects Topical tretinoin has been shown to be fetotoxic in rabbits when administered 0.5 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). Oral tretinoin has been shown to be fetotoxic, resulting in skeletal variations and increased intrauterine death in rats when administered 2.5 mg/kg/day (20 times the maximum human systemic dose adjusted for total body surface area).

There are, however, no adequate and well-controlled studies in pregnant women. Tretinoin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tretinoin is administered to a nursing woman. Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 have not been established. Geriatric Use Safety and effectiveness in a geriatric population have not been established. Clinical studies of RETIN-A did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of follicular epithelial cells with decreased microcomedo formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Tretinoin Cream · Obagi Cosmeceuticals LLC [US FDA-approved label, version 13, February 11, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=745cc3ce-60b4-4479-a055-316817567949
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .